Skip to main content
Premium Trial:

Request an Annual Quote

Serimmune COVID Antibody Epitope Mapping Service

Serimmune has launched a COVID antibody epitope mapping discovery service, which leverages the company's serum epitope repertoire analysis (SERA) technology. The service requires 100 ul of serum or plasma per sample, which Serimmune analyzes for IgG and/or IgM antibodies using its proprietary, 10-billion-member, random, bacterial peptide display library. The service provides a composite score of the antibody epitopes identified in each sample to those observed in cohorts of individuals with mild, moderate, and severe COVID-19 disease. It also provides single amino acid-resolution epitope data across the entire SARS-CoV-2 proteome for each sample and shows how it compares to a large cohort of pre-pandemic controls and SARS-COV-2 positive samples, the company said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.